As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Valneva Se. The largest reported stake is Bpifrance Participations S.A.'s, at 9.3%. 4 filings are on record since September 5, 2025 (Schedule 13D/A, May 12, 2026).
Sell to companies like Valneva Se? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Bpifrance Participations S.A. · Percent: 9.3% · SCHEDULE 13D/A
- · Holder: Frazier Life Sciences Public Fund, L.P. · Percent: 3.6% · SCHEDULE 13G
- · Holder: Bpifrance Participations S.A. · Percent: 10.5% · SCHEDULE 13D/A
- · Holder: Bpifrance Participations S.A. · Percent: 11.6% · SCHEDULE 13D/A
Valneva Se has 4 Schedule 13D or 13G filings on record since 2025-09-05. 1 holder's latest filing reports 5% or more of ordinary shares, nominal value euro0.15 per share, represented by american depository shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bpifrance Participations S.A. | 9.3% | 14,317,670 | SCHEDULE 13D/A, 2026-05-12 | 2026-05-05 |
| Frazier Life Sciences Public Fund, L.P. | 3.6% | 6,879,516 | SCHEDULE 13G, 2026-05-12 | 2026-05-05 |
Holding shares or following this stake? See who's behind Valneva Se and the warning signs.
Free to see. No signup.
Keep reading
More on Valneva Se and the records around it.
Valneva Se elsewhere on the record
Companies that share a holder
- Bpifrance Participations S.A. also filed stake reports on 4 other companies: Cellectis S.A. (Nov 2026), Pasqal Holding SA (Sep 2026), Constellium SE (May 2026)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
Watch Valneva Se
Get an email when Valneva Se files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Valneva Se?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Valneva Se: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Valneva Se covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Bpifrance Participations S.A.
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The Issuer completed an EUR84 million reserved offering subscribed by a limited number of investors which is expected to close on May 5, 2026 (the "Reserved Offering"). In the Reserved Offering, the Issuer issued 15,893,817 new ordinary shares (the "New Shares"), and one share warrant is attached to each New Share. The Reporting Persons did not participate in the Reserved Offering. The New Shares issued in the Reserved Offering represented an increase in the share capital of the Issuer which resulted in a dilution of the Reporting Persons' holdings. In the past 60 days, Bpifrance Participations sold 356,003 Ordinary Shares. Bpifrance Participations sold the amount of Ordinary Shares on the date and at the price set forth below in open market transactions. Unless otherwise noted, the sales of the Ordinary Shares were sold in multiple transactions at varying prices. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this Schedule 13D. March 10, 2026: - 226,532 Ordinary Shares at a weighted average price of EUR4.93 per share (multiple transactions at prices ranging from EUR4.85 to EUR5.03, inclusive). March 11, 2026: - 5,318 Ordinary Shares at a weighted average price of EUR4.96 per share …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-12; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-05 | Bpifrance Participations S.A. | 11.6% | SCHEDULE 13D/A |
| 2026-03-10 | Bpifrance Participations S.A. | 10.5% | SCHEDULE 13D/A |
| 2026-05-12 | Bpifrance Participations S.A. | 9.3% | SCHEDULE 13D/A |
| 2026-05-12 | Frazier Life Sciences Public Fund, L.P. | 3.6% | SCHEDULE 13G |
Questions about who owns Valneva Se
Who owns Valneva Se?
On this page, one holder's latest ownership filing reports 5% or more of Valneva Se: Bpifrance Participations S.A. (9.3%, Schedule 13D/A, filed 2026-05-12).
When did Bpifrance Participations S.A. buy into Valneva Se?
The filings give report dates, not purchase dates. The earliest filing from Bpifrance Participations S.A. on this page is the Schedule 13D/A, filed 2025-09-05, reporting 11.6%; its latest, Schedule 13D/A filed 2026-05-12, reports 9.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Valneva Se. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.